An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-07-01
Edice:	EBioMedicine
Témata:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!